eligibility criteria included regular menstrual cycles, no oral contraceptives, a greater than 3-fold increase in 5 year risk, and baseline ki-67 â‰¥2% in areas of hyperplasia in breast tissue sampled by random periareolar fine needle aspiration (rpfna) during the follicular phase of the menstrual cycle.